MicroRNAs and uses thereof
Described herein are novel polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
1. A nucleic acid selected from the group consisting of:
(a) a nucleic acid of 18-24 nucleotides comprising at least 18 contiguous nucleotides identical to SEQ ID NO: 18611;
(b) a DNA encoding the nucleic acid of (a), wherein the DNA is identical in length to (a);
(c) the complement of one of the nucleic acids of (a) and (b), wherein the complement is identical in length to the one of the nucleic acids of (a) and (b);
wherein the nucleic acid comprises a non-naturally occurring nucleotide.
2. A probe comprising a heterologous sequence, wherein the heterologous sequence consists a nucleic acid sequence selected from the group consisting of:
(a) a sequence of 18-24 nucleotides comprising at least 18 contiguous nucleotides identical to SEQ ID NO: 18611;
(b) a DNA encoding the sequence of (a), wherein the DNA is identical in length to (a);
(c) the complement of one of the sequences of (a) and (b), wherein the complement is identical in length to the one of the sequences of (a) and (b),
wherein the probe comprises at least one of a non-naturally occurring nucleotide and a label.
3. A vector comprising a heterologous sequence, wherein the heterologous sequence consists of a nucleic acid sequence selected from the group consisting of
(a) a sequence of 18-24 nucleotides comprising at least 18 contiguous nucleotides identical to SEQ ID NO: 18611;
(b) a DNA encoding the sequence of (a), wherein the DNA is identical in length to (a);
(c) the complement of one of the sequences of (a) and (b), wherein the complement is identical in length to the one of the sequences of (a) and (b).